Thirty-one adult patients with infections due to anaerobic bacteria were treated with cefamandole. BacterQides fragilis group (17) and Bacteroides melaninogenicus (13) were the most frequent anaerobes isolated. Duration of therapy varied from 2 to 49 days. Results were judged satisfactory in 26 cases, and unsatisfactory in 1 case. Four cases could not be evaluated. Adverse reactions occurred in 16 patients and included positive direct Coombs' test without hemolysis, transient liver function abnormalities, phlebitis, reversible neutropenia, fever, eosinophilia, and toxic epidermal necrolysis. The more significant reactions were associated with prolonged therapy. None was lethal. These data suggest that cefamandole is effective in treatment of most anaerobic infections.
Cefamandole nafate, a new parenteral cephalosporin, has a broader spectrum of activity against both aerobic and anaerobic bacteria than cephalothin or cefazolin (9, 10) . In vitro it is active against a wide range of gram-positive and gram-negative aerobic and anaerobic bacteria (5, 13) . On the basis of these reports, we evaluated cefamandole in the treatment of anaerobic infections.
(The results presented here have been reported, in part, in abstract form [R. N. Greenberg, M. C. Scalcini, C. V. Sanders, and A. C. Lewis, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 18th, Atlanta, Ga., Abstr. no. 360, 1978] .) MATERIALS AND METHODS Patients. Thirty-one patients with anaerobic infections who had been hospitalized at Charity Hospital of New Orleans between July 1977 and August 1978 were admitted to the study. Patients were included only if they (i) were over 13 years of age, (ii) were not pregnant, (iii) had no history of allergy to penicillin or cephalosporin antibiotics, and (iv) had not received any antibiotics once culture specimens were taken. Informed consent was obtained from each patient before cefamandole therapy was started.
In all but three patients anaerobic organisms were isolated from culture material. In the three patients in whom anaerobes were not recovered, the pus obtained smelled foul, its Gram stain revealed a variety of pleomorphic gram-negative organisms, and its culture did not grow any aerobic gram-negative organism. The clinical diagnoses in these three patients were lung abscess, salpingitis, and postabortal endometritis.
Isolation and identification of bacteria. Most specimens were collected by transtracheal aspiration (15) or by aspiration of material directly from an abscess (9) . The specimens were immediately injected into oxygen-free vials (Port-a-Cul; Baltimore Biological Laboratory [BBL], Cockeysville, Md.) and transported to the laboratory. When specimens could not be aspirated, specifically in cases of postpartum, postabortal, or intrauterine device-related endometritis, the endocervical pus was collected with a sterile swab and transported to the laboratory in oxygen-free tubes (BBL).
Specimens for anaerobic culture were inoculated onto prereduced blood agar and kanamycin-vancomycin blood agar plates and into Schaedler broth. All anaerobic media were supplemented with hemin (5 ,ug/ml) and menadione (0.5 jig/ml) and incubated in an anaerobic chamber (National Appliance Company, Hollywood, Fla.) containing an anaerobic gas mixture of 85% N, 10% H2, and 5% CO2. Anaerobic bacteria were identified by colony morphology, reaction to Gram stain, growth on selective media, gas chromatography of fermentative products, and biochemical reactions. The criteria used for these procedures are those outlined by the Anaerobic Laboratory at Virginia Polytechnic Institute (8) . Biochemical reactions were carried out by means of the Minitek Miniaturized Differentiation System (BBL) (16) . Aerobic bacteria were isolated and identified by standard laboratory techniques (11) .
Susceptibility tests. Antibiotic susceptibilities of anaerobic bacteria were determined by using the following agar-dilution procedure. After each organism had been isolated and checked for purity, it was inoculated onto a prereduced blood agar plate and incubated at 37°C for 48 h under anaerobic conditions. On the day before testing, serial dilutions of the antibiotic to be tested were added to tubes of melted Brucella agar (cooled to 48°C) containing hemin (5 i.g/ml), menadione (0.5 ,g/ml), and 5% laked sheep blood. The contents of each tube were mixed and poured into square petri dishes with 13- (7) .
Therapeutic regimen and evaluation of response. Most patients were initially treated with intravenous (i.v.) cefamandole in a dose of 2 g over 10 to 20 min every 4 h. In life-threatening infection, a 2-g dose was administered every 3 h. Doses were adjusted in patients with renal failure as follows: 2 g every 6 h (serum creatinine, 1.5 to 2 mg/100 ml), 1.5 g every 6 h (serum creatinine, 2 to 4 mg/100 ml), 1 g every 6 h (serum creatinine, 4 to 10 mg/100 ml), and 0.5 g every 8 h (serum creatinine greater than 10 mg/100 ml). Duration of therapy ranged from 2 to 49 days. Tobra 15 min after the infusion was 96 ,ug/ml, a serum level 3 h after the infusion was 3 ,tg/ml, a spot urine level was 10,300 ,ug/ml, and an empyema level was undetectable.
Clinical response. Twenty-six patients responded satisfactorily and one unsatisfactorily to therapy, and four could not be evaluated ( Table 3 ). The single patient in whom treatment failed had an aspiration pneumonitis. The culture of his transtracheal aspirate yielded a Bacteroides melaninogenicus (MIC = 1 ,ug/ml), an Enterobacter aerogenes (MIC c 30 ,ug/ml), and a B. fragilis (MIC > 64 ug/ml). The patients who could not be evaluated included: one patient with a lung abscess, who died of pulmonary embolus 2 days after therapy was begun; one patient with a lung abscess, who died of gastric hemorrhage after 6 days of therapy; and two patients with thoracic empyemas that were not adequately drained during the study.
B. fragilis groups were isolated in 11 patients; the response was considered satisfactory in 8 and unsatisfactory in 1, and could not be evaluated in 2. Ruptured appendix 2 2 with peritonitis Lung abscess with 2 2 empyema Ruptured tubo-1 1 ovarian abscess 174, 1977) . In 26 of 27 (96%) patients, the drug was clearly effective in treating the infection; 4 patients could not be adequately evaluated. The patient in whom treatment failed had aspiration pneumonitis that worsened despite 4 days of cefamandole administration. From a transtracheal aspirate were isolated E. aerogenes, B. melaninogenicus, and B. fragilis; the first two were susceptible to cefamandole, but the B. fr-agilis had an MIC > 64 ,ug/ml.
Defining resistance to cefamandole is difficult. Levels in serum after i.v. infusion of 2 g of cefamandole for 10 to 30 min are between 147 and 240 ,ug/ml; however, the half-life after i.v. administration is about 0.7 h because the drug is rapidly cleared by the kidneys. At 4 h after VOL. 15, 1979 on October 23, 2017 by guest http://aac.asm.org/ The incidence of significant adverse reactions, which included three cases of reversible neutropenia, one case of drug-related fever with eosinophilia, one case of eosinophilia, and one case of toxic epidermal necrolysis (1, 19) , was higher in our study than incidences reported in other trials with cefamandole (12, 15) . This finding is probably related to the large daily dose coupled with the long duration of treatment (Table 6) ; the mean duration of therapy at onset of these reactions was 28 days (17-to 40-day range). None of the side effects resulted in death.
Overall, cefamandole appeared effective in treating most of our patients. It should be noted, however, the dosage used was 12 to 16 g per day i.v.. Although none of the drug's toxicities was irreversible or lethal, a significant number of adverse reactions were encountered with prolonged usage at this high dose level. Our in vitro data substantiate earlier reports (9, 10) that most anaerobes (excluding the B. fragilis group) are susceptible to cefamandole at c32 ,ug/ml. We believe cefamandole has a place in the treatment of anaerobic infection, but should not be regarded as a first-line drug. Its use should be undertaken with caution because strains of resistant B. fragilis group are not uncommon.
